SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences - Quaterly Results

09 May 2023 Evaluate
The sales is pegged at Rs. 26.11 millions for the March 2023 quarter. The mentioned figure indicates a decline of about -38.14% as against Rs. 42.21 millions during the year-ago period.The Net Loss for the quarter ended March 2023 is Rs. -22.50 millions as compared to Net Loss of Rs. -85.54 millions of corresponding quarter ended March 2022 Operating profit Margin for the quarter ended March 2023 improved to -5.24% as compared to -73.54% of corresponding quarter ended March 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 26.11 42.21 -38.14 135.39 118.44 14.31 135.39 118.44 14.31
Other Income 56.02 1.18 4647.46 84.49 16.01 427.73 84.49 16.01 427.73
PBIDT -5.24 -73.54 -92.87 -192.95 -350.41 -44.94 -192.95 -350.41 -44.94
Interest 0.54 0.98 -44.90 2.89 5.30 -45.47 2.89 5.30 -45.47
PBDT -5.78 -74.52 -92.24 -135.84 -318.55 -57.36 -135.84 -318.55 -57.36
Depreciation 16.72 11.02 51.72 65.43 43.93 48.94 65.43 43.93 48.94
PBT -22.50 -85.54 -73.70 -201.27 -362.48 -44.47 -201.27 -362.48 -44.47
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -22.50 -85.54 -73.70 -201.27 -362.48 -44.47 -201.27 -362.48 -44.47
Equity 218.07 145.38 50.00 218.07 145.38 50.00 218.07 145.38 50.00
PBIDTM(%) -20.07 -174.22 -88.48 -142.51 -295.85 -51.83 -142.51 -295.85 -51.83

Suven Life Sciences Share Price

195.90 -0.10 (-0.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×